|Slideshows|October 9, 2020

7 New Drugs for Primary Care: Q3 2020

The end of another quarter means a new list of FDA-approved drugs for conditions treated in primary care. Are you up-to-date? Click through to find out.

As another quarter rounds out, a new batch of drugs have been approved by the US Food and Drug Administration for conditions often seen in primary care. Scroll through the slides below to find details on a first-in-class topical androgen receptor inhibitor for the treatment of acne; a novel attachment inhibitor for adults with multidrug-resistant HIV-1 infection; and 5 more.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

7 New Drugs for Primary Care: Q3 2020

Newsletter

Related Content

When Daily Oral PrEP Is Not the Best Fit: Lessons From Clinical Practice

Moderate-to-Severe OSA Tied to Doubled Risk of Brain Microbleeds: Daily Dose

Tezepelumab Achieves Dual Benefit in Adults with Severe Asthma: Daily Dose

FDA Approves Lerodalcibep, Third-Generation PCSK9 Inhibitor, to Treat Hypercholesterolemia, Including HeFH

How Long-Acting Injectable PrEP Reshapes the Patient–Provider Relationship

Latest CME

Medical Crossfire®: Optimal Approaches to Evaluating and Addressing Pain in the Patient With Sickle Cell Disease

Community Practice Connections™: 21st Annual Meeting of the International Society of Gastrointestinal Oncology

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Rounds with Dr Jabbour: Breaking Barriers in ALL Treatment

Rapid Reviews in Retina™: Emerging Updates from Fall 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Missouri

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | New Mexico

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Addressing Health Care Inequities™: Taking a More Mindful Approach to the Care of Every Patient Presenting With ATTR-CM

Clinical Case Vignette Series™: 3rd Annual International Congress on Pediatric Oncology

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

22nd Annual Meeting of the International Society of Gastrointestinal Oncology

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | North Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | West Virginia

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Tennessee

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Washington

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | South Carolina

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Texas

Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

Cases and Conversations™: Optimizing Patient Outcomes in Pediatric/AYA and Adult ALL/LBL With Asparaginase Therapies and Combinations

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Nevada

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Show Me the Data™: Pushing CAR Ts Forward Across Lymphoid Malignancies…Accelerating Access in the Community and the Treatment Strategies for the Road Ahead

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kentucky

Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next in B-Cell Malignancies

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Evolving Treatment Paradigms for Patients With Hemoglobinopathies

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New York

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Iowa

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Advancements in Chronic Myeloid Leukemia: Treatment Strategies, Mechanisms, and Patient Management

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Minnesota

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies

Cases and Conversations™: The Rationale for Utilizing Nonfactor Replacement Therapies in Hemophilia Care

Community Practice Connections™: 19th Annual New York Lung Cancers Symposium®

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Molecular Testing and Personalized Strategies in Pancreatic Cancer: Targeting NRG1 and Rare Drivers With an Optimized Approach

Optimizing Care for Patients With Tardive Dyskinesia

EnVision Summit

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

‘REEL’ Time Patient Counseling™: Improving Quality of Life for Patients with Sickle Cell Disease – Disease Modifying Therapy Vs. Curative Approaches

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

19th Annual New York GU Cancers Congress™

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Medical Crossfire® – From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

(CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

11th Annual School of Gastrointestinal Oncology® (SOGO®)

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment